Purpose: The utilization of controller medications before initiating a long-acting β 2-adrenergic agonist (LABA) before and after the Food and Drug Administration (FDA) alerts is examined. Methods: ...
New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center's Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease ...
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...
Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
· Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients · Arcapta Neohaler showed significant ...
New York, NY, December 2, 2009 – Commonly prescribed beta 2 adrenergic agonist drugs for the treatment of asthma in pregnant women as well as pre-term labor may increase the incidence of ...
This was a retrospective analysis of electronic pharmacy and medical claims from a commercial health plan located in the states of California, Texas, Oklahoma, Oregon, and Washington, with annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback